When.com Web Search

  1. Ads

    related to: lipitor pfizer astellas 5 000

Search results

  1. Results From The WOW.Com Content Network
  2. Lipitor? What Was That Again? - AOL

    www.aol.com/2012/07/31/lipitor-what-was-that-again

    Pfizer (NYS: PFE) used to sell Lipitor exclusively in the United States. And it was a huge component of the company's revenue and earnings. Honest. I swear. You certainly wouldn't know it from the ...

  3. Pfizer agrees to pay $93 million to settle Lipitor antitrust ...

    www.aol.com/news/pfizer-agrees-pay-93-million...

    Pfizer introduced Lipitor in 1997, and the drug drove more than $130 billion in sales during its first 14 years on the market. The pharma distributors claimed Pfizer fraudulently sought to extend ...

  4. Pfizer Losing Lipitor Patent: What Investors Need to Know - AOL

    www.aol.com/news/2011-12-01-pfizer-losing...

    Here's what's going on, what you need to know, and what you should do.The cold, hard factsThe Financial Times is reporting that pharmaceutical giant Pfizer (NYS: PFE) Pfizer Losing Lipitor Patent ...

  5. Atorvastatin - Wikipedia

    en.wikipedia.org/wiki/Atorvastatin

    From 1996 to 2012, under the trade name Lipitor, atorvastatin became the world's best-selling medication of all time, with more than $125 billion in sales over approximately 14.5 years. [ 117 ] and $13 billion a year at its peak, [ 118 ] Lipitor alone "provided up to a quarter of Pfizer Inc.'s annual revenue for years."

  6. Pfizer's Long-Shot Lipitor Gamble - AOL

    www.aol.com/news/2011-08-04-pfizers-long-shot...

    If an article from The Wall Street Journal about Pfizer's (NYS: PFE) plan to get an over-the-counter version of Lipitor approved is correct, big pharma is likely fighting a losing battle. On the ...

  7. Torcetrapib - Wikipedia

    en.wikipedia.org/wiki/Torcetrapib

    Torcetrapib (CP-529,414, Pfizer) was a drug being developed to treat hypercholesterolemia (elevated cholesterol levels) and prevent cardiovascular disease.Its development was halted in 2006 when phase III studies showed excessive all-cause mortality in the treatment group receiving a combination of atorvastatin (Lipitor) and torcetrapib.